secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001447028-24-000061
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus shareholders approve 9.5M share increase under 2016 Omnibus Plan
------------------------------------------------------------------------

- Amendment increases aggregate authorized shares by 9,500,000 common shares.
- All seven director nominees (Torti, McElhaugh, Burgess, Henriques, Manchester, Meyers, Rewolinski) elected.
- Non-binding advisory vote on named executive officer compensation approved (99.3M for, 13.5M against).
- Ernst & Young LLP appointed as independent auditor for FY 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000061/0001447028-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000061/abus-20240522.htm
  HTML page:      https://secwatch.observer/filing/0001447028-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer